Neuro Pace Inc NPCE
Institutional shares held
21.7 Million
23.2K
calls
800
puts
Total value of holdings
$254M
$270K
calls
$9K
puts
Market Cap
$290M
24,846,900
Shares Out.
Institutional ownership
87.51%
# of Institutions
68
We take great care to ensure that the data presented and summarized in this overview for NeuroPace Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NPCE
View all-
Kck Ltd. Tortola, D85.27MShares$61.6 Million78.74% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.41MShares$39.8 Million1.03% of portfolio
-
Morgan Stanley New York, NY2.49MShares$29.1 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.43MShares$28.4 Million1.9% of portfolio
-
Kent Lake Pr LLC Anasco, PR1.48MShares$17.3 Million7.02% of portfolio
-
Kent Lake Capital LLC Mill Valley, CA1.14MShares$13.4 Million3.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.06MShares$12.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY671KShares$7.84 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny643KShares$7.51 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY593KShares$6.92 Million0.09% of portfolio
Latest Institutional Activity in NPCE
Top Purchases
Top Sells
About NPCE
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Insider Transactions at NPCE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 22
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
237
-0.17%
|
$2,370
$10.94 P/Share
|
|
Apr 22
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
237
-0.26%
|
$2,370
$10.94 P/Share
|
|
Mar 24
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
11,700
+11.4%
|
-
|
|
Mar 10
2025
|
Joel Becker CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
58,500
+35.46%
|
-
|
|
Mar 10
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
11,700
+7.89%
|
-
|
|
Mar 03
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,337
-1.06%
|
$14,707
$11.81 P/Share
|
|
Mar 03
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,337
-1.66%
|
$14,707
$11.81 P/Share
|
|
Feb 27
2025
|
Joel Becker CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
4,506
-8.59%
|
$54,072
$12.56 P/Share
|
|
Feb 27
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,430
-1.74%
|
$17,160
$12.56 P/Share
|
|
Feb 27
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,430
-1.12%
|
$17,160
$12.56 P/Share
|
|
Feb 21
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
78,334
-48.86%
|
$1,018,342
$13.72 P/Share
|
|
Feb 20
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,405
-7.23%
|
$47,670
$14.23 P/Share
|
|
Feb 20
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,405
-2.6%
|
$47,670
$14.23 P/Share
|
|
Feb 20
2025
|
Kck Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,270,845
-100.0%
|
$47,437,605
$9.4 P/Share
|
|
Jan 30
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
200
-0.23%
|
$3,000
$15.0 P/Share
|
|
Jan 29
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
100
-0.11%
|
$1,500
$15.0 P/Share
|
|
Jan 24
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,200
-3.55%
|
$48,000
$15.01 P/Share
|
|
Jan 22
2025
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
265
-0.56%
|
$3,710
$14.04 P/Share
|
|
Jan 22
2025
|
Rebecca Kuhn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
265
-0.22%
|
$3,710
$14.04 P/Share
|
|
Dec 03
2024
|
Martha Morrell CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,413
-2.9%
|
$15,543
$11.93 P/Share
|
Last 12 Months Summary
Buy / Acquisition
81.9K
Shares
From
3
Insiders
| Grant, award, or other acquisition | 81.9K shares |
|---|
Sell / Disposition
5.75M
Shares
From
6
Insiders
| Open market or private sale | 5.7M shares |
|---|---|
| Payment of exercise price or tax liability | 45.2K shares |